Login to Your Account



Celgene Changing Course On Thalomid In Multiple Myeloma

By Brady Huggett


Friday, March 8, 2002
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription